Asensus Surgical (ASXC) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 was $2.2 million, doubling from $1.1 million in Q2 2023, driven by a partial Senhance System sale and higher lease revenue.

• Net loss for Q2 2024 was $25.7 million ($0.09/share), compared to $20.7 million ($0.09/share) in Q2 2023; adjusted net loss improved to $18.1 million ($0.07/share) from $20.3 million ($0.09/share) year-over-year.

• Cash and cash equivalents at June 30, 2024, were $7.8 million, down from $17.1 million at year-end 2023.

• Entered a definitive merger agreement with KARL STORZ, offering $0.35 per share in cash for all outstanding shares; if not approved, bankruptcy is expected.

• Proxy advisory firms ISS and Glass Lewis recommend voting for the merger; over 80% of proxies cast so far support it.

Financial highlights

• Product revenue for Q2 2024 rose to $1.4 million from $0.3 million year-over-year; lease revenue increased to $0.6 million.

• Gross loss for Q2 2024 was $0.5 million, improved from $2.0 million in Q2 2023.

• Operating expenses for Q2 2024 were $23.1 million, up from $18.9 million in Q2 2023.

• Operating loss for Q2 2024 was $23.5 million, up from $20.9 million in Q2 2023.

• Weighted average shares outstanding for Q2 2024 were 272.3 million.

Outlook and guidance

• If the proposed merger with KARL STORZ is not approved, the company expects to seek bankruptcy protection due to inability to meet financial obligations.

• No alternative offers or higher bids have been received since the merger announcement.

• Over $300 million would be needed to support operations through 2027 if the merger is not approved.

• Management believes current cash, including bridge funding, is sufficient to pursue merger approval.